Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Statistics
Share Statistics
Sagimet Biosciences has 30.67M shares outstanding. The number of shares has increased by -3.88% in one year.
| Shares Outstanding | 30.67M |
| Shares Change (YoY) | -3.88% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 23.27M |
| Failed to Deliver (FTD) Shares | 314 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 4.17M, so 13.6% of the outstanding shares have been sold short.
| Short Interest | 4.17M |
| Short % of Shares Out | 13.6% |
| Short % of Float | 20.44% |
| Short Ratio (days to cover) | 1.37 |
Valuation Ratios
The PE ratio is -2.03 and the forward PE ratio is -1.31. Sagimet Biosciences's PEG ratio is -0.02.
| PE Ratio | -2.03 |
| Forward PE | -1.31 |
| PS Ratio | 28.35 |
| Forward PS | 1.1 |
| PB Ratio | 0.62 |
| P/FCF Ratio | -2.39 |
| PEG Ratio | -0.02 |
Enterprise Valuation
Sagimet Biosciences Inc. has an Enterprise Value (EV) of 56.62B.
| EV / Earnings | -2031.14 |
| EV / Sales | 28309.97 |
| EV / EBITDA | -1841.9 |
| EV / EBIT | -1841.9 |
| EV / FCF | -2382.39 |
Financial Position
The company has a current ratio of 17.09, with a Debt / Equity ratio of 0.
| Current Ratio | 17.09 |
| Quick Ratio | 17.09 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.07 |
| Cash Flow / Debt | -365.63 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.31% and return on capital (ROIC) is -33.73%.
| Return on Equity (ROE) | -0.31% |
| Return on Assets (ROA) | -0.29% |
| Return on Capital (ROIC) | -33.73% |
| Revenue Per Employee | $250,000 |
| Profits Per Employee | $-3,484,500 |
| Employee Count | 8 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -44.8% in the last 52 weeks. The beta is 2.62, so Sagimet Biosciences's price volatility has been higher than the market average.
| Beta | 2.62 |
| 52-Week Price Change | -44.8% |
| 50-Day Moving Average | 4.55 |
| 200-Day Moving Average | 4.23 |
| Relative Strength Index (RSI) | 35.51 |
| Average Volume (20 Days) | 1M |
Income Statement
In the last 12 months, Sagimet Biosciences had revenue of 2M and earned -27.88M in profits. Earnings per share was -2.66.
| Revenue | 2M |
| Gross Profit | 2M |
| Operating Income | -30.74M |
| Net Income | -27.88M |
| EBITDA | -30.74M |
| EBIT | -30.74M |
| Earnings Per Share (EPS) | -2.66 |
Balance Sheet
The company has 75.14M in cash and 65K in debt, giving a net cash position of 75.07M.
| Cash & Cash Equivalents | 75.14M |
| Total Debt | 65K |
| Net Cash | 75.07M |
| Retained Earnings | -249.74M |
| Total Assets | 174.78M |
| Working Capital | 153.1M |
Cash Flow
In the last 12 months, operating cash flow was -23.77M and capital expenditures 0, giving a free cash flow of -23.77M.
| Operating Cash Flow | -23.77M |
| Capital Expenditures | 0 |
| Free Cash Flow | -23.77M |
| FCF Per Share | -2.27 |
Margins
Gross margin is 100%, with operating and profit margins of -1.54K% and -1.39K%.
| Gross Margin | 100% |
| Operating Margin | -1.54K% |
| Pretax Margin | -1.39K% |
| Profit Margin | -1.39K% |
| EBITDA Margin | -1.54K% |
| EBIT Margin | -1.54K% |
| FCF Margin | -1.19K% |
Dividends & Yields
SGMT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -77.1% |
| FCF Yield | -22.44% |
Analyst Forecast
The average price target for SGMT is $30, which is 769.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $30 |
| Price Target Difference | 769.6% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 14.67 |
| Piotroski F-Score | 1 |